Caribou Biosciences (NASDAQ:CRBU) Insider Barbara Mcclung Sells 6,938 Shares

Caribou Biosciences, Inc. (NASDAQ:CRBU) insider Barbara Mcclung sold 6,938 shares of the company’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $1.96, for a total transaction of $13,598.48. Following the completion of the transaction, the insider directly owned 481,564 shares in the company, valued at $943,865.44. This trade represents a 1.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Caribou Biosciences Stock Performance

Shares of NASDAQ CRBU traded up $0.22 during trading hours on Tuesday, hitting $2.14. The stock had a trading volume of 4,611,005 shares, compared to its average volume of 1,124,577. The company has a market capitalization of $200.03 million, a P/E ratio of -1.26 and a beta of 2.61. The firm’s 50-day moving average price is $1.61 and its two-hundred day moving average price is $1.90. Caribou Biosciences, Inc. has a 52 week low of $0.66 and a 52 week high of $3.54.

Institutional Investors Weigh In On Caribou Biosciences

Several large investors have recently modified their holdings of the stock. Next Capital Management LLC bought a new position in shares of Caribou Biosciences during the 2nd quarter worth approximately $25,000. Bronte Capital Management Pty Ltd. acquired a new position in Caribou Biosciences during the fourth quarter worth $25,000. Creative Planning acquired a new position in Caribou Biosciences during the second quarter worth $25,000. R Squared Ltd bought a new position in shares of Caribou Biosciences during the third quarter valued at $29,000. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of Caribou Biosciences in the 2nd quarter valued at $30,000. 77.51% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CRBU. Weiss Ratings reissued a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Wednesday, January 21st. HC Wainwright lifted their price objective on Caribou Biosciences from $3.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Citigroup boosted their price objective on Caribou Biosciences from $5.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, November 3rd. Finally, Truist Financial set a $7.00 target price on Caribou Biosciences in a research note on Tuesday, November 4th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $8.00.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.